Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?

Abstract

Several randomised controlled trials (RCTs) have proven the efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA), such as liraglutide, in both improving glycaemic control, inducing sustained significant weight loss, and reducing mortality in patients with diabetes. These benefits have been demonstrated in myriad cohorts, as patients with type 2 diabetes (T2D), prediabetes and normoglycemia all exhibit positive outcomes (1-4).